A Prospective, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group, 12-week Study to Evaluate the Safety and Tolerability of Macitentan in Subjects With Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH) Due to Left Ventricular Dysfunction
Phase of Trial: Phase II
Latest Information Update: 22 Feb 2018
At a glance
- Drugs Macitentan (Primary)
- Indications Pulmonary hypertension
- Focus Adverse reactions
- Acronyms MELODY-1
- Sponsors Actelion Pharmaceuticals
- 01 Feb 2018 Results published in the European Respiratory Journal
- 21 Nov 2015 Status changed from active, no longer recruiting to completed as per European Clinical Trials Database.
- 17 Sep 2015 Planned End Date changed from 1 Oct 2015 to 1 Nov 2015, as reported by ClinicalTrials.gov.